<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01405885</url>
  </required_header>
  <id_info>
    <org_study_id>FLU-101</org_study_id>
    <nct_id>NCT01405885</nct_id>
  </id_info>
  <brief_title>A Study of DNA Vaccine With Electroporation for the Prevention of Disease Caused by H1 and H5 Influenza Virus</brief_title>
  <official_title>Phase I, Open Label Study to Evaluate Safety, Tolerability and Immunogenicity of Multiple Combinations of H1 and H5 Influenza Hemagglutinin Plasmids Administered ID Followed by in Vivo Electroporation With CELLECTRA®-3P in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inovio Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Inovio Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I, parallel design open label study to evaluate safety, tolerability and&#xD;
      immunogenicity of nine different formulation of two individual H1 and one H5 HA plasmid&#xD;
      administered intradermally followed by electroporation in healthy adults&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The use of DNA plasmids containing genes that express viral antigens may be a promising way&#xD;
      to formulate a vaccine that can effectively prevent infection and disease caused by the H5N1&#xD;
      avian influenza virus and H1N1 influenza viruses. Plasmid vectors are simple to construct and&#xD;
      are easy to manufacture at a relatively low cost. Vaccination with plasmids that express&#xD;
      influenza proteins should induce the development of serum antibodies and might also induce&#xD;
      significant quantities of secretory IgA antibodies and/or CMI. The DNA sequences included in&#xD;
      the vaccine could also result in the proliferation of T lymphocytes that could broaden the&#xD;
      effectiveness of the vaccine to include variant strains of H5N1 and H1N1 with antigenically&#xD;
      modified HA (i.e., drifted strains).&#xD;
&#xD;
      Electroporation (EP) is a technology in which a transmembrane electrical field is applied to&#xD;
      increase the permeability of cell membranes to create microscopic pathways (pores) and&#xD;
      thereby enhance the uptake of drugs, vaccines, or other agents into target cells. Their&#xD;
      presence allows macromolecules, ions, and water to pass from one side of the membrane to the&#xD;
      other. The presence of a constant field influences the kinetics of directional translocation&#xD;
      of the macromolecular plasmid, such that the plasmid delivery in vivo has been sufficient to&#xD;
      achieve physiological levels of secreted proteins. ID injection of a plasmid followed by EP&#xD;
      has been used very successfully to deliver therapeutic genes that encode for a variety of&#xD;
      hormones, cytokines, or enzymes in a variety of species. EP is currently being used in humans&#xD;
      to deliver cancer vaccines and therapeutics as well as in gene therapy. The expression levels&#xD;
      are increased by as much as 3 orders of magnitude over plasmid injection alone.&#xD;
&#xD;
      The use of EP via the CELLECTRA® device should increase the expression of H5N1 and H1N1&#xD;
      influenza virus genes in the study vaccines.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of nine different formulation of multiple combination of H1 and H5 HA plasmid administered ID followed by electroporation in healthy adult subjects</measure>
    <time_frame>Day 0 through Month 12</time_frame>
    <description>Frequency and severity of local and systemic reactogenicity signs and symptoms, adverse events and serious adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Humoral and cellular immune responses</measure>
    <time_frame>Day 0 through Month 12</time_frame>
    <description>Magnitude and frequency of antibody and cell mediated immune response to influenza proteins</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tolerability and immunogenicity of multiple formulations of H1 and H5 HA plasmids administered ID followed by electroporation to seasonal influenza vaccine</measure>
    <time_frame>Day 0 through Month 12</time_frame>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">116</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Arm A - 0.9mg of INO-3605</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B - 0.9mg of INO-3609</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C- 0.9mg of INO-3401</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D- 0.3mg of INO-3609</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm E - 0.45mg each INO-3605 , INO-3609</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm F - 0.3mg each of INO-3401,INO-3605,INO-3609</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm G - 0.9mg of INO-3609</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm H - 0.9mg of INO-3609</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm I - Seasonal influenza vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm J - 1.8mg of INO-3609</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>INO-3605</intervention_name>
    <description>0.9mg of INO-3605 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.</description>
    <arm_group_label>Arm A - 0.9mg of INO-3605</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>INO-3609</intervention_name>
    <description>0.9mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.</description>
    <arm_group_label>Arm B - 0.9mg of INO-3609</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>INO-3401</intervention_name>
    <description>0.9mg of 3401 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.</description>
    <arm_group_label>Arm C- 0.9mg of INO-3401</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>INO-3609</intervention_name>
    <description>0.3mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.</description>
    <arm_group_label>Arm D- 0.3mg of INO-3609</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>INO-3605 AND INO-3609</intervention_name>
    <description>0.45mg each of INO-3605 AND INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.</description>
    <arm_group_label>Arm E - 0.45mg each INO-3605 , INO-3609</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>INO-3510</intervention_name>
    <description>0.3mg each of INO-3605, INO-3609 AND INO-3401 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.</description>
    <arm_group_label>Arm F - 0.3mg each of INO-3401,INO-3605,INO-3609</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>INO-3609</intervention_name>
    <description>0.9mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 16 and 24.</description>
    <arm_group_label>Arm G - 0.9mg of INO-3609</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>INO-3609</intervention_name>
    <description>0.9mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0 and Week 8</description>
    <arm_group_label>Arm H - 0.9mg of INO-3609</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Seasonal Influenza vaccine</intervention_name>
    <description>0.5ml of vaccine delivered IM</description>
    <arm_group_label>Arm I - Seasonal influenza vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>INO-3609</intervention_name>
    <description>1.8mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.</description>
    <arm_group_label>Arm J - 1.8mg of INO-3609</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent in accordance with institutional guidelines. If required by&#xD;
             local law, candidates must also authorize the release and use of protected health&#xD;
             information (PHI);&#xD;
&#xD;
          -  Adults of either gender 18-55 years of age at entry;&#xD;
&#xD;
          -  Healthy subjects as judged by the Investigator based on medical history, physical&#xD;
             examination, and normal results for an ECG, CBC, serum chemistries, and urinalysis&#xD;
             done up to 4 weeks prior to enrollment and administration of vaccination ± EP;&#xD;
&#xD;
          -  Current nonsmoker;&#xD;
&#xD;
          -  Women of child-bearing potential (WOCBP) agree to remain sexually abstinent, use&#xD;
             medically effective contraception (oral contraception, barrier methods, spermicide,&#xD;
             etc), or have a partner who is sterile (i.e., vasectomy) until 12 weeks after last&#xD;
             vaccination;&#xD;
&#xD;
          -  Able and willing to comply with all study procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Positive serological test for Human Immunodeficiency Virus, hepatitis C virus or&#xD;
             hepatitis B virus surface antigen (HBsAg) or Grade 3 or greater CPK at screening;&#xD;
&#xD;
          -  Pregnant or breastfeeding subjects;&#xD;
&#xD;
          -  Any concurrent condition requiring the continued use of systemic or topical steroids&#xD;
             at or near the injection site (excluding inhaled and eye drop-containing&#xD;
             corticosteroids) or the use of other immunosuppressive agents. All other&#xD;
             corticosteroids must be discontinued &gt; 4 weeks prior to Day 0 of study vaccine&#xD;
             administration;&#xD;
&#xD;
          -  Administration of any blood product within 3 months of enrollment;&#xD;
&#xD;
          -  Prior receipt of any investigational or licensed H5N1 influenza vaccine at any time;&#xD;
&#xD;
          -  Subjects with contraindications to influenza vaccination other than egg allergy (such&#xD;
             as a history of Guillain-Barre Syndrome after receiving influenza vaccine);&#xD;
&#xD;
          -  Administration of any vaccine within 6 weeks of enrollment;&#xD;
&#xD;
          -  Participation in a study with an investigational compound or device within 4 weeks of&#xD;
             signing informed consent;&#xD;
&#xD;
          -  Subjects with cardiac pre-excitation syndromes (such as Wolff-Parkinson-White);&#xD;
&#xD;
          -  Subjects with a history of seizures (unless seizure free for 5 years);&#xD;
&#xD;
          -  Subjects with tattoos, scars, or active lesions/rashes within 2 cm of the site of&#xD;
             vaccination ± EP;&#xD;
&#xD;
          -  Subjects with any implantable leads;&#xD;
&#xD;
          -  Active drug or alcohol use or dependence that, in the opinion of the investigator,&#xD;
             would interfere with adherence to study requirements;&#xD;
&#xD;
          -  Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for&#xD;
             treatment of either a psychiatric or physical (i.e. infections disease) illness must&#xD;
             not be enrolled into this study;&#xD;
&#xD;
          -  Any other conditions judged by the investigator that would limit the evaluation of a&#xD;
             subject.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Bagarazzi, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Inovio Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Miami Research Associates</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vince and Associates</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SNBL</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.inovio.com</url>
    <description>Sponsor's address</description>
  </link>
  <verification_date>February 2014</verification_date>
  <study_first_submitted>July 27, 2011</study_first_submitted>
  <study_first_submitted_qc>July 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2011</study_first_posted>
  <last_update_submitted>February 28, 2014</last_update_submitted>
  <last_update_submitted_qc>February 28, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Universal Influenza</keyword>
  <keyword>Intradermal DNA vaccine</keyword>
  <keyword>Electroporation</keyword>
  <keyword>H1 and H5</keyword>
  <keyword>DNA Vaccination</keyword>
  <keyword>Influenza</keyword>
  <keyword>INO-3510</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

